(BCAB) Bioatla - Overview
Stock: Antibody-Drug Conjugates, Bispecific Antibodies, Immuno-Oncology
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 154% |
| Relative Tail Risk | -11.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.06 |
| Alpha | -78.45 |
| Character TTM | |
|---|---|
| Beta | 1.453 |
| Beta Downside | 1.931 |
| Drawdowns 3y | |
|---|---|
| Max DD | 95.59% |
| CAGR/Max DD | -0.65 |
Description: BCAB Bioatla December 23, 2025
BioAtla, Inc. (NASDAQ: BCAB) is a clinical-stage biopharma focused on antibody-based therapeutics that are conditionally active (CAB) to improve selectivity against solid tumors. Its lead candidates are mecbotamab vedotin (BA3011) for undifferentiated pleomorphic sarcoma and NSCLC, and ozuriftamab vedotin (BA3021) for melanoma and head-and-neck squamous cell carcinoma, both ADCs designed to release payload only within the tumor micro-environment.
The pipeline also includes Evalstotug (BA3071), a CAB anti-CTLA-4 antibody covering melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific targeting adenocarcinomas; BA3361, a CAB-Nectin-4 ADC; BA3142, a dual-CAB T-cell engager against B7-H3; and a preclinical CAB-Nectin-4 × CAB-CD3 construct. The company was founded in 2007 and operates out of San Diego, California.
As of the most recent 10-Q (Q2 2024), BioAtla reported $78 million in cash and equivalents, giving it ~18 months of runway at its current burn rate of ~$4.3 million per month. The ADC market is projected to exceed $12 billion by 2028, driven by higher efficacy and safety profiles, which underpins the commercial upside of BioAtla’s CAB platform. Recent Phase 1/2 data for BA3011 showed a disease control rate of 68 % in a small NSCLC cohort, a metric that, if confirmed, could position the asset favorably against competing ADCs.
Investors should monitor the timing of the upcoming IND filings for BA3182 and BA3361, as well as any partnership announcements that could accelerate late-stage development and mitigate cash-flow risk.
For a deeper, data-driven valuation, consider reviewing ValueRay’s analyst platform.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -64.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -3.59 > 0.02 and ΔFCF/TA -222.1 > 1.0 |
| NWC/Revenue: -75.58% < 20% (prev 323.5%; Δ -399.1% < -1%) |
| CFO/TA -3.59 > 3% & CFO -57.1m > Net Income -64.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 0.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (58.7m) vs 12m ago 21.54% < -2% |
| Gross Margin: -13.24% > 18% (prev 0.92%; Δ -1415 % > 0.5%) |
| Asset Turnover: 28.15% > 50% (prev 20.42%; Δ 7.74% > 0%) |
| Interest Coverage Ratio: -19.09 > 6 (EBITDA TTM -67.7m / Interest Expense TTM -3.58m) |
Altman Z'' -15.00
| A: -0.52 (Total Current Assets 9.67m - Total Current Liabilities 18.0m) / Total Assets 15.9m |
| B: -33.69 (Retained Earnings -535.9m / Total Assets 15.9m) |
| C: -1.75 (EBIT TTM -68.3m / Avg Total Assets 39.1m) |
| D: -11.37 (Book Value of Equity -535.9m / Total Liabilities 47.1m) |
| Altman-Z'' Score: -136.9 = D |
What is the price of BCAB shares?
Over the past week, the price has changed by -21.71%, over one month by -51.08%, over three months by -67.11% and over the past year by -57.88%.
Is BCAB a buy, sell or hold?
- StrongBuy: 2
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BCAB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10 | 4661.9% |
| Analysts Target Price | 10 | 4661.9% |
| ValueRay Target Price | 0.1 | -52.4% |
BCAB Fundamental Data Overview February 02, 2026
P/B = 2.681
Revenue TTM = 11.0m USD
EBIT TTM = -68.3m USD
EBITDA TTM = -67.7m USD
Long Term Debt = 6.18m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.17m USD (from shortTermDebt, last quarter)
Debt = 6.18m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.14m USD (from netDebt column, last quarter)
Enterprise Value = 15.1m USD (17.2m + Debt 6.18m - CCE 8.32m)
Interest Coverage Ratio = -19.09 (Ebit TTM -68.3m / Interest Expense TTM -3.58m)
EV/FCF = -0.26x (Enterprise Value 15.1m / FCF TTM -57.1m)
FCF Yield = -378.3% (FCF TTM -57.1m / Enterprise Value 15.1m)
FCF Margin = -518.8% (FCF TTM -57.1m / Revenue TTM 11.0m)
Net Margin = -588.2% (Net Income TTM -64.7m / Revenue TTM 11.0m)
Gross Margin = -13.24% ((Revenue TTM 11.0m - Cost of Revenue TTM 12.5m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.95 (Enterprise Value 15.1m / Total Assets 15.9m)
Interest Expense / Debt = 23.78% (Interest Expense 1.47m / Debt 6.18m)
Taxrate = 21.0% (US default 21%)
NOPAT = -53.9m (EBIT -68.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.54 (Total Current Assets 9.67m / Total Current Liabilities 18.0m)
Debt / Equity = -0.20 (negative equity) (Debt 6.18m / totalStockholderEquity, last quarter -31.2m)
Debt / EBITDA = 0.03 (negative EBITDA) (Net Debt -2.14m / EBITDA -67.7m)
Debt / FCF = 0.04 (negative FCF - burning cash) (Net Debt -2.14m / FCF TTM -57.1m)
Total Stockholder Equity = -8.29m (last 4 quarters mean from totalStockholderEquity)
RoA = -165.6% (out of range, set to none)
RoE = 780.3% (negative equity) (Net Income TTM -64.7m / Total Stockholder Equity -8.29m)
RoCE = 3234 % (out of range, set to none) (EBIT -68.3m / Capital Employed (Equity -8.29m + L.T.Debt 6.18m))
RoIC = -378.2% (out of range, set to none) (NOPAT -53.9m / Invested Capital 14.3m)
WACC = 13.26% (E(17.2m)/V(23.4m) * Re(11.27%) + D(6.18m)/V(23.4m) * Rd(23.78%) * (1-Tc(0.21)))
Discount Rate = 11.27% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.59%
Fair Price DCF = unknown (Cash Flow -57.1m)
EPS Correlation: 89.86 | EPS CAGR: 51.75% | SUE: 3.35 | # QB: 1
Revenue Correlation: 16.52 | Revenue CAGR: -5.31% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.20 | Chg30d=+0.095 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.92 | Chg30d=+0.280 | Revisions Net=+2 | Growth EPS=+14.8% | Growth Revenue=+0.0%